ストックスクリーナーアプリを入手
1.25
3.85%
-0.05
アフターアワーズ：
1.25
Cardiff Oncology Inc (CRDF) 最新ニュース
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Cardiff Oncology director Gary Pace buys $36,600 in stock By Investing.com - Investing.com Australia
Cardiff Oncology director Gary Pace buys $36,600 in stock - Investing.com UK
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock - Investing.com
Form 4 Cardiff Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
CRDF: Phase II Update; Survival Advantage Extended - Yahoo Finance
Cardiff Oncology (CRDF) Stifel 2025 Healthcare Conference Summary - Quartr
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cardiff Oncology (CRDF) director receives 40,565 stock options grant - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
Lucid Capital Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus
CRDF Downgraded by Craig-Hallum -- Price Target Lowered to $2.00 - GuruFocus
Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Update - GuruFocus
Cardiff Oncology unveils promising Phase 2 onvansertib data - TipRanks
Onvansertib Phase 2 results move Cardiff Oncology (NASDAQ: CRDF) toward Phase 3 - Stock Titan
Cardiff Oncology Inc Call on Updated Phase 2 CRDF-004 Transcript - GuruFocus
Craig-Hallum Downgrades Cardiff Oncology(CRDF.US) to Hold Rating, Announces Target Price $2 - Moomoo
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib By Investing.com - Investing.com Australia
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in RAS-Mutated Metastatic Colorectal Cancer, Plans Registrational Study - Quiver Quantitative
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - The Manila Times
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades - marketscreener.com
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
0.48%
大文字化:
|
ボリューム (24 時間):